ME02440B - Miševi koji ispoljavaju laki lanac sa ljudskim lambda promenljivim regionom i mišjim konstantnim regionom - Google Patents

Miševi koji ispoljavaju laki lanac sa ljudskim lambda promenljivim regionom i mišjim konstantnim regionom

Info

Publication number
ME02440B
ME02440B MEP-2016-132A MEP13216A ME02440B ME 02440 B ME02440 B ME 02440B ME P13216 A MEP13216 A ME P13216A ME 02440 B ME02440 B ME 02440B
Authority
ME
Montenegro
Prior art keywords
mice
gene
lambda
mouse
human
Prior art date
Application number
MEP-2016-132A
Other languages
German (de)
English (en)
French (fr)
Inventor
Lynn Macdonald
Sean Stevens
Cagan Gurer
Andrew J Murphy
Karolina A Hosiawa
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of ME02440B publication Critical patent/ME02440B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Position Input By Displaying (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)

Claims (1)

1.Miš koji obuhvata endogeni λ (lambda) alel lakog lanca koji obuhvata nepreraspoređeni ljudski promenljivi lambda (hVλ) i nepreraspoređeni ljudski spojni (hJλ) segment gena, pri čemu miš obuhvata brisanje prve Vλ-Jλ-Cλ skupine gena pomenutog endogenog mišjeg λ alela lakog lanca i zamenu, u celini ili delimično, Vλ-Jλ segmente gena druge Vλ-Jλ-Cλ skupine gena pomenutog alela sa ljudskim Vλ i Jλ segmentima gena koji su funkcionalno povezani na nedirnuti mišji lambda konstantni (Cλ) region gena pomenute druge Vλ-Jλ-Cλ skupine gena tako da miš ispoljava laki lanac izveden izhVλ hJλ i mišji Cλ gen, pri čemu se endogeni pojačavači Enh
MEP-2016-132A 2010-06-22 2011-06-22 Miševi koji ispoljavaju laki lanac sa ljudskim lambda promenljivim regionom i mišjim konstantnim regionom ME02440B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35731710P 2010-06-22 2010-06-22
US35731410P 2010-06-22 2010-06-22
PCT/US2011/041366 WO2011163311A1 (en) 2010-06-22 2011-06-22 Mice expressing alight chain with human lambda variable and mouse constant regions
EP11728508.0A EP2480675B1 (en) 2010-06-22 2011-06-22 Mice expressing a light chain with human lambda variable and mouse constant regions

Publications (1)

Publication Number Publication Date
ME02440B true ME02440B (me) 2016-09-20

Family

ID=44509861

Family Applications (5)

Application Number Title Priority Date Filing Date
MEP-2019-128A ME03386B (me) 2010-06-22 2011-06-22 Hibridni laki lanac imunoglobulina koji ispoljavaju miševi
MEP-2016-132A ME02440B (me) 2010-06-22 2011-06-22 Miševi koji ispoljavaju laki lanac sa ljudskim lambda promenljivim regionom i mišjim konstantnim regionom
MEP-2017-244A ME02902B (me) 2010-06-22 2011-06-22 Transgeni miševi sa modifikovanim lokusom endogenog lambda imunoglobulina
MEP-2016-87A ME02444B (me) 2010-06-22 2011-06-22 Hibridni laki lanac imunoglobulina koji ispouavaju miševi
MEP-2016-119A ME02442B (me) 2010-06-22 2011-06-22 Miševi koji ispoljavaju laki lanac hibridnog imunoglobulina sa promenljivim regionom čovjeka

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MEP-2019-128A ME03386B (me) 2010-06-22 2011-06-22 Hibridni laki lanac imunoglobulina koji ispoljavaju miševi

Family Applications After (3)

Application Number Title Priority Date Filing Date
MEP-2017-244A ME02902B (me) 2010-06-22 2011-06-22 Transgeni miševi sa modifikovanim lokusom endogenog lambda imunoglobulina
MEP-2016-87A ME02444B (me) 2010-06-22 2011-06-22 Hibridni laki lanac imunoglobulina koji ispouavaju miševi
MEP-2016-119A ME02442B (me) 2010-06-22 2011-06-22 Miševi koji ispoljavaju laki lanac hibridnog imunoglobulina sa promenljivim regionom čovjeka

Country Status (30)

Country Link
US (22) US9012717B2 (me)
EP (7) EP2480675B1 (me)
JP (16) JP6009441B2 (me)
KR (16) KR101991234B1 (me)
CN (4) CN103068993B (me)
AU (1) AU2011271046B2 (me)
BR (3) BR112012032991B1 (me)
CA (2) CA2803864C (me)
CY (5) CY1117537T1 (me)
DK (5) DK3034608T3 (me)
ES (5) ES2646052T3 (me)
HR (5) HRP20160497T1 (me)
HU (5) HUE036597T2 (me)
IL (12) IL300712B2 (me)
LT (4) LT2568049T (me)
ME (5) ME03386B (me)
MX (6) MX347322B (me)
MY (6) MY195214A (me)
NO (1) NO2905338T3 (me)
NZ (6) NZ627119A (me)
PL (5) PL3034608T3 (me)
PT (5) PT2568049T (me)
RS (5) RS58736B1 (me)
RU (3) RU2601297C2 (me)
SG (4) SG186390A1 (me)
SI (5) SI2905338T1 (me)
SM (5) SMT201900241T1 (me)
TR (1) TR201905992T4 (me)
WO (2) WO2011163314A1 (me)
ZA (5) ZA201300063B (me)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
LT2346994T (lt) 2008-09-30 2022-03-10 Ablexis, Llc Knock-in pelė, skirta chimerinių antikūnų gamybai
MX2011007660A (es) 2008-12-18 2011-08-17 Kingdon Craig R Animales transgenicos no humanos que expresan anticuerpos humanizados y usos de los mismos.
PT2564695E (pt) 2009-07-08 2015-06-03 Kymab Ltd Modelos animais e moléculas terapêuticas
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
CA2789154C (en) 2010-02-08 2024-06-11 Regeneron Pharmaceuticals, Inc. Common light chain mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
ES2984483T3 (es) 2010-03-31 2024-10-29 Ablexis Llc Ingeniería genética de ratones para la producción de anticuerpos quiméricos
ME03386B (me) 2010-06-22 2020-01-20 Regeneron Pharma Hibridni laki lanac imunoglobulina koji ispoljavaju miševi
RU2580017C2 (ru) 2010-07-26 2016-04-10 Трианни, Инк. Трансгенные животные и способы применения
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
RU2612903C2 (ru) 2010-08-02 2017-03-13 Ридженерон Фармасьютикалз, Инк. Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены
RS66089B1 (sr) 2011-08-05 2024-11-29 Regeneron Pharma Humanizovani miševi univerzalnog lakog lanca
EP3839049A3 (en) 2011-09-19 2021-10-20 Kymab Limited Antibodies, variable domains & chains tailored for human use
JP2014531452A (ja) * 2011-09-19 2014-11-27 カイマブ・リミテッド 動物、レパートリーおよび方法
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) * 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
SI2793567T1 (sl) 2011-12-20 2019-05-31 Regeneron Pharmaceuticals, Inc. Humanizirane lahkoverižne miši
RU2018128915A (ru) 2012-03-16 2019-02-18 Регенерон Фармасьютикалз, Инк. ОТЛИЧНЫЕ ОТ ЧЕЛОВЕКА ЖИВОТНЫЕ, ЭКСПРЕССИРУЮЩИЕ ЧУВСТВИТЕЛЬНЫЕ К рН ПОСЛЕДОВАТЕЛЬНОСТИ ИММУНОГЛОБУЛИНОВ
SG10201607727PA (en) 2012-03-16 2016-11-29 Regeneron Pharma Mice that produce antigen-binding proteins with ph-dependent binding characteristics
EP3348140B1 (en) 2012-03-16 2020-12-30 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified rodents for generating the same
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
SG11201405059XA (en) 2012-03-28 2014-09-26 Kymab Ltd Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
CN105734081A (zh) 2013-02-20 2016-07-06 瑞泽恩制药公司 具有修饰的免疫球蛋白重链序列的非人类动物
EP2967013B1 (en) * 2013-03-13 2019-01-16 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
ES2829376T3 (es) 2013-03-14 2021-05-31 Univ Erasmus Med Ct Rotterdam Mamífero no humano transgénico para la producción de anticuerpos
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
PL3046412T3 (pl) * 2013-09-18 2019-11-29 Regeneron Pharma Przekształcone histydyną łańcuchy lekkie przeciwciał i genetycznie zmodyfikowane zwierzęta inne niż człowiek do ich wytwarzania
ES2993142T3 (en) 2013-10-01 2024-12-23 Kymab Ltd Animal models and therapeutic molecules
TW201532513A (zh) * 2014-01-10 2015-09-01 Alfur Fu-Hsin Hung 能產生比小鼠ＩgＥ量高出許多的人源化ＩgＥ之基因轉殖動物
CN106164092A (zh) * 2014-03-21 2016-11-23 瑞泽恩制药公司 表现不同结合特征的vl抗原结合蛋白
EP3895528A1 (en) 2014-03-21 2021-10-20 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
SG10201810507WA (en) 2014-06-06 2018-12-28 Bristol Myers Squibb Co Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
MX2017003640A (es) 2014-09-19 2017-10-31 Regeneron Pharma Receptores antigenicos quimericos.
US10894818B2 (en) 2014-10-03 2021-01-19 Massachusetts Institute Of Technology Antibodies that bind Ebola glycoprotein and uses thereof
HUE050596T2 (hu) 2014-11-21 2020-12-28 Bristol Myers Squibb Co Antitestek CD73 ellen és azok felhasználásai
EP3945096A1 (en) 2014-12-19 2022-02-02 Regenesance B.V. Antibodies that bind human c6 and uses thereof
MX389267B (es) 2014-12-23 2025-03-20 Bristol Myers Squibb Co Anticuerpos contra el inmunorreceptor de células t con dominios de inmunoglobulina y de porción inhibidora con base en tirosina del inmumorreceptor (tigit).
WO2016124709A1 (de) 2015-02-05 2016-08-11 Basf Se Solarkraftwerk mit einem ersten wärmeträgerkreislauf und einem zweiten wärmeträgerkreislauf
JP2018508224A (ja) 2015-03-19 2018-03-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗原を結合する軽鎖可変領域を選択する非ヒト動物
CA2987410A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Antibodies against ox40 and uses thereof
MX2017016502A (es) 2015-06-29 2018-03-12 Univ Rockefeller Anticuerpos contra cd40 con actividad agonista mejorada.
CN105274116B (zh) * 2015-10-21 2020-09-29 重庆金迈博生物科技有限公司 一种制备人源化抗体的核酸分子及其应用
EP3377532B1 (en) 2015-11-19 2022-07-27 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
WO2017095939A1 (en) 2015-12-03 2017-06-08 Trianni, Inc. Enhanced immunoglobulin diversity
IL260743B2 (en) 2016-02-04 2024-03-01 Trianni Inc Advanced production of antibodies
JP2019514844A (ja) 2016-03-04 2019-06-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｃｄ７３抗体を用いた併用療法
SG11201807677YA (en) 2016-03-04 2018-10-30 Univ Rockefeller Antibodies to cd40 with enhanced agonist activity
CN109476742B (zh) 2016-05-09 2023-04-14 百时美施贵宝公司 Tl1a抗体及其用途
CN109475109B (zh) 2016-05-20 2021-10-29 瑞泽恩制药公司 用于使用多个引导rna来破坏免疫耐受性的方法
PT4218408T (pt) 2016-06-03 2025-03-26 Regeneron Pharma Roedores que expressam desoxinucleotidil-transferase terminal exógena
WO2017214089A1 (en) * 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
US20170372142A1 (en) * 2016-06-27 2017-12-28 Facebook, Inc. Systems and methods for identifying matching content
US20190248893A1 (en) 2016-07-14 2019-08-15 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
US10981976B2 (en) 2016-08-31 2021-04-20 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
CR20190193A (es) 2016-10-13 2019-08-21 Massachusetts Inst Technology Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos
JP6868250B2 (ja) 2016-10-31 2021-05-12 国立大学法人鳥取大学 ヒト抗体産生非ヒト動物及びそれを用いたヒト抗体作製法
SMT202000558T1 (it) * 2016-11-04 2020-11-10 Regeneron Pharma Animali non umani aventi un locus di catena leggera di immunoglobulina lambda ingegnerizzata
US11142570B2 (en) 2017-02-17 2021-10-12 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
PL4140297T3 (pl) 2017-12-05 2025-08-25 Regeneron Pharmaceuticals, Inc. Myszy mające zmodyfikowany sposobami inżynierii łańcuch lekki lambda immunoglobuliny i ich zastosowania
EP3737700A1 (en) 2018-01-12 2020-11-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
US11242393B2 (en) 2018-03-23 2022-02-08 Bristol-Myers Squibb Company Antibodies against MICA and/or MICB and uses thereof
US20210051929A1 (en) 2018-03-24 2021-02-25 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
JP7328243B2 (ja) 2018-03-26 2023-08-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 治療薬を試験するためのヒト化げっ歯類
CA3102441C (en) 2018-06-08 2023-06-13 Crystal Bioscience Inc. Transgenic animal for producing diversified antibodies that have the same light chain i
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
EP3872506A4 (en) 2018-10-26 2023-01-11 Vehicle Energy Japan Inc. Battery control device
NZ777032A (en) 2018-11-16 2024-07-26 Bristol Myers Squibb Co Anti-nkg2a antibodies and uses thereof
KR20230128134A (ko) 2019-01-22 2023-09-01 브리스톨-마이어스 스큅 컴퍼니 Il-7r 알파 서브유닛에 대한 항체 및 이의 용도
AU2020226865A1 (en) 2019-02-22 2021-07-29 Regeneron Pharmaceuticals, Inc. Rodents having genetically modified sodium channels and methods of use thereof
JP2022535418A (ja) * 2019-06-05 2022-08-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド カッパ遺伝子座から発現される限られたラムダ軽鎖レパートリーを有する非ヒト動物及びその使用
DK3993623T3 (da) * 2019-07-01 2025-05-26 Zoetis Services Llc Transgene gnavere og fremgangsmåder til anvendelse deraf
KR20220110233A (ko) 2019-12-02 2022-08-05 리제너론 파마슈티칼스 인코포레이티드 펩티드-mhc ii 단백질 작제물 및 그의 용도
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
WO2021261620A1 (ko) * 2020-06-25 2021-12-30 주식회사 휴맵 이형접합성 형질전환 동물
JP2023540808A (ja) 2020-09-11 2023-09-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗原特異的抗体の同定及び産生
WO2022132943A1 (en) 2020-12-16 2022-06-23 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
WO2022140494A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same
EP4051700B1 (en) 2020-12-23 2025-05-07 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
WO2023199655A1 (ja) 2022-04-13 2023-10-19 日本精工株式会社 軸受装置の状態の検出方法、検出装置、およびプログラム
USD999969S1 (en) * 2022-04-29 2023-09-26 Shenzhen Intellirocks Tech. Co., Ltd. Lamp
EP4658687A1 (en) 2023-01-31 2025-12-10 University of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
TW202509069A (zh) 2023-05-04 2025-03-01 美商諾瓦森塔股份有限公司 抗cd161抗體及其使用方法
WO2025184208A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK1471142T3 (da) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimere receptor-biblioteker under anvendelse af fagemider
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
DK1500329T3 (da) * 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
CN101498731A (zh) * 2000-05-18 2009-08-05 日本烟草产业株式会社 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7041870B2 (en) * 2000-11-30 2006-05-09 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
GB0031284D0 (en) * 2000-12-21 2001-01-31 Ks Biomedix Ltd High affinity antibodies
CN100448992C (zh) * 2001-05-11 2009-01-07 麒麟医药株式会社 含人抗体λ轻链基因的人类人工染色体
GB0115256D0 (en) * 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
EP1461442B1 (en) * 2001-11-30 2017-09-06 Amgen Fremont Inc. Transgenic animals bearing human ig lambda light chain genes
US20030217171A1 (en) 2002-05-17 2003-11-20 Von Stuermer Wolfgang R. Self-replicating and self-installing software apparatus
EP1644417B1 (en) * 2003-07-15 2014-04-30 Therapeutic Human Polyclonals, Inc. Humanized immunoglobulin loci
CN1605628A (zh) * 2003-09-03 2005-04-13 中国疾病预防控制中心病毒病预防控制所 Cho细胞生产的人源抗甲肝病毒基因工程抗体
RU2398777C2 (ru) * 2004-08-05 2010-09-10 Дженентек, Инк. ГУМАНИЗИРОВАННЫЕ АНТАГОНИСТЫ, НАПРАВЛЕННЫЕ ПРОТИВ c-met
DK2767161T3 (en) 2004-10-19 2018-05-07 Regeneron Pharma Method of generating an animal homozygous for genetic modification
EP1831257B9 (en) * 2004-12-29 2011-05-04 Yuhan Corporation Humanized antibody specific for tumor necrosis factor-alpha
JP5514539B2 (ja) 2006-03-31 2014-06-04 メダレックス・リミテッド・ライアビリティ・カンパニー ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物
JP2010501165A (ja) * 2006-08-22 2010-01-21 ジーツー インフラメイション プロプライエタリー リミテッド 抗体の作製方法
CA2664343C (en) * 2006-10-02 2016-04-26 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
US7864492B2 (en) 2006-10-31 2011-01-04 Siemens Industry, Inc. Systems and methods for arc fault detection
DE102007045897A1 (de) 2007-09-26 2009-04-09 Carl Zeiss Microimaging Gmbh Verfahren zur mikroskopischen dreidimensionalen Abbildung einer Probe
WO2009129247A2 (en) * 2008-04-14 2009-10-22 Innovative Targeting Solutions Inc. Sequence diversity generation in immunoglobulins
EP2669298A3 (en) * 2008-05-23 2014-02-26 Ablexis, LLC Single variable immunoglobulin domain comprising VL-DH-JL
LT2346994T (lt) 2008-09-30 2022-03-10 Ablexis, Llc Knock-in pelė, skirta chimerinių antikūnų gamybai
MX2011007660A (es) * 2008-12-18 2011-08-17 Kingdon Craig R Animales transgenicos no humanos que expresan anticuerpos humanizados y usos de los mismos.
PT2564695E (pt) 2009-07-08 2015-06-03 Kymab Ltd Modelos animais e moléculas terapêuticas
CA2789154C (en) * 2010-02-08 2024-06-11 Regeneron Pharmaceuticals, Inc. Common light chain mouse
CN103228130B (zh) 2010-06-17 2016-03-16 科马布有限公司 动物模型及治疗分子
ME03386B (me) 2010-06-22 2020-01-20 Regeneron Pharma Hibridni laki lanac imunoglobulina koji ispoljavaju miševi

Also Published As

Publication number Publication date
BR112012032991A2 (pt) 2015-10-06
MX2012015300A (es) 2013-05-01
SG186391A1 (en) 2013-01-30
NZ707200A (en) 2016-04-29
ME02442B (me) 2016-09-20
MX336344B (es) 2016-01-15
MY195214A (en) 2023-01-11
PL2480676T3 (pl) 2016-10-31
KR20190014576A (ko) 2019-02-12
RU2016119423A (ru) 2018-11-07
US9334333B2 (en) 2016-05-10
EP3034608B1 (en) 2019-01-30
IL300712B1 (en) 2024-07-01
RU2013102595A (ru) 2014-07-27
IL255179B (en) 2018-06-28
AU2011271046B2 (en) 2015-10-01
CY1122877T1 (el) 2021-05-05
KR101934852B1 (ko) 2019-01-04
HK1170766A1 (zh) 2013-03-08
US10266803B2 (en) 2019-04-23
US20180064078A1 (en) 2018-03-08
KR102211911B1 (ko) 2021-02-05
CN104342455A (zh) 2015-02-11
US9844212B2 (en) 2017-12-19
IL300712B2 (en) 2024-11-01
JP2025027148A (ja) 2025-02-26
BR112012032991A8 (pt) 2020-09-29
KR20130027555A (ko) 2013-03-15
NZ626979A (en) 2015-05-29
US20190203171A1 (en) 2019-07-04
PT2480676E (pt) 2016-06-09
US9206261B2 (en) 2015-12-08
US20170107484A1 (en) 2017-04-20
SG10201504324UA (en) 2015-07-30
US9029628B2 (en) 2015-05-12
US9066502B2 (en) 2015-06-30
PL2568049T3 (pl) 2017-03-31
KR102266097B1 (ko) 2021-06-18
PT2905338T (pt) 2017-11-10
PL2905338T3 (pl) 2018-01-31
CY1117692T1 (el) 2017-05-17
EP2905338B1 (en) 2017-08-02
CY1119478T1 (el) 2018-03-07
IL223719A (en) 2016-10-31
RS56589B1 (sr) 2018-02-28
IL282872A (en) 2021-06-30
US9540452B2 (en) 2017-01-10
IL259965A (en) 2018-07-31
US20150320023A1 (en) 2015-11-12
JP2018023403A (ja) 2018-02-15
HUE029692T2 (en) 2017-03-28
SI2480675T1 (sl) 2016-08-31
CN103068994B (zh) 2016-01-20
JP2016010415A (ja) 2016-01-21
HUE029691T2 (en) 2017-03-28
IL244450A (en) 2017-11-30
EP3456832A1 (en) 2019-03-20
NZ627119A (en) 2015-05-29
CY1117537T1 (el) 2017-04-26
JP2019033765A (ja) 2019-03-07
JP2017012204A (ja) 2017-01-19
US20150173331A1 (en) 2015-06-25
EP2480675B1 (en) 2016-04-06
EP3205726A1 (en) 2017-08-16
US20150246976A1 (en) 2015-09-03
IL244450A0 (en) 2016-04-21
MY157477A (en) 2016-06-15
IL291301B1 (en) 2023-03-01
CA2803864A1 (en) 2011-12-29
ZA201506598B (en) 2017-03-29
US9206263B2 (en) 2015-12-08
EP2568049B1 (en) 2016-04-13
US9850462B2 (en) 2017-12-26
HUE030285T2 (en) 2017-05-29
EP2480676A1 (en) 2012-08-01
HRP20171666T1 (hr) 2017-12-15
RS58736B1 (sr) 2019-06-28
US9163092B2 (en) 2015-10-20
US20160057979A1 (en) 2016-03-03
KR102059909B1 (ko) 2019-12-27
CN104404050B (zh) 2018-06-08
MY165287A (en) 2018-03-21
KR101991234B1 (ko) 2019-06-20
KR102506001B1 (ko) 2023-03-07
US9206262B2 (en) 2015-12-08
US20240327785A1 (en) 2024-10-03
KR20210134424A (ko) 2021-11-09
ZA201300063B (en) 2014-09-25
SMT201700506T1 (it) 2018-01-11
CN103068994A (zh) 2013-04-24
PT3034608T (pt) 2019-05-28
SMT201600229B (me) 2016-08-31
LT2905338T (lt) 2017-12-27
IL223720A (en) 2017-05-29
HRP20190807T1 (hr) 2019-08-23
CA2804311A1 (en) 2011-12-29
ME02902B (me) 2018-04-20
RS55037B1 (sr) 2016-12-30
WO2011163314A1 (en) 2011-12-29
EP2480675A1 (en) 2012-08-01
DK2480676T3 (en) 2016-06-20
NZ605751A (en) 2014-10-31
JP2013531501A (ja) 2013-08-08
DK3034608T3 (da) 2019-05-06
KR102462042B1 (ko) 2022-11-03
SI2568049T1 (sl) 2016-10-28
KR102320944B1 (ko) 2021-11-04
SI3034608T1 (sl) 2019-06-28
MY194456A (en) 2022-11-30
KR20130121814A (ko) 2013-11-06
LT2568049T (lt) 2016-10-10
CA2804311C (en) 2017-09-12
KR20190073584A (ko) 2019-06-26
IL255179A0 (en) 2017-12-31
JP5988969B2 (ja) 2016-09-07
ZA201300062B (en) 2014-09-25
US20130323790A1 (en) 2013-12-05
TR201905992T4 (tr) 2019-05-21
RU2590594C2 (ru) 2016-07-10
PL3034608T3 (pl) 2019-08-30
RU2016119423A3 (me) 2019-11-19
DK2480675T3 (en) 2016-08-01
RU2724736C2 (ru) 2020-06-25
NO2905338T3 (me) 2017-12-30
ES2575223T3 (es) 2016-06-27
IL264634B (en) 2019-09-26
JP6243384B2 (ja) 2017-12-06
US20200239837A1 (en) 2020-07-30
KR102001430B1 (ko) 2019-07-18
HRP20160865T1 (hr) 2016-10-07
AU2011271043A9 (en) 2015-10-01
BR112012033248A2 (pt) 2017-11-28
MX2012015298A (es) 2013-05-01
MY195212A (en) 2023-01-11
BR112012032991B1 (pt) 2021-08-10
US9394373B2 (en) 2016-07-19
US9012717B2 (en) 2015-04-21
ZA201404601B (en) 2016-02-24
ME02444B (me) 2016-09-20
KR101945352B1 (ko) 2019-02-07
HK1183321A1 (en) 2013-12-20
US20170258059A1 (en) 2017-09-14
JP2017006152A (ja) 2017-01-12
US20190153384A1 (en) 2019-05-23
JP6963542B2 (ja) 2021-11-10
JP7236409B2 (ja) 2023-03-09
MY195217A (en) 2023-01-11
LT2480675T (lt) 2016-10-10
KR20180135997A (ko) 2018-12-21
RS55042B1 (sr) 2016-12-30
NZ605758A (en) 2014-08-29
US20150089680A1 (en) 2015-03-26
HRP20160497T1 (hr) 2016-07-15
IL269078A (en) 2019-11-28
KR20190014578A (ko) 2019-02-12
HUE044001T2 (hu) 2019-09-30
MX347318B (es) 2017-04-21
AU2011271043B2 (en) 2015-10-01
WO2011163311A1 (en) 2011-12-29
KR20210073609A (ko) 2021-06-18
DK2905338T3 (da) 2017-11-06
SI2480676T1 (sl) 2016-10-28
US20120070861A1 (en) 2012-03-22
KR20190142436A (ko) 2019-12-26
ZA201404600B (en) 2015-09-30
JP2021061863A (ja) 2021-04-22
JP2020062061A (ja) 2020-04-23
US9035128B2 (en) 2015-05-19
SI2905338T1 (sl) 2017-12-29
SMT201600213B (it) 2016-08-31
US20120073004A1 (en) 2012-03-22
CN103068993A (zh) 2013-04-24
US9006511B2 (en) 2015-04-14
US20140137275A1 (en) 2014-05-15
IL291301A (en) 2022-05-01
RU2013102596A (ru) 2014-07-27
BR122020013427B1 (pt) 2021-08-03
JP2013532974A (ja) 2013-08-22
JP2022066449A (ja) 2022-04-28
ES2721749T3 (es) 2019-08-05
HK1168384A1 (zh) 2012-12-28
JP2018201528A (ja) 2018-12-27
US20160060359A1 (en) 2016-03-03
US9399683B2 (en) 2016-07-26
MX347322B (es) 2017-04-21
MX348942B (es) 2017-07-04
JP6545773B2 (ja) 2019-07-17
KR20190049932A (ko) 2019-05-09
ME03386B (me) 2020-01-20
ES2570131T3 (es) 2016-05-17
KR20230036157A (ko) 2023-03-14
IL300712A (en) 2023-04-01
IL269078B (en) 2021-05-31
IL282872B (en) 2022-04-01
JP2018201527A (ja) 2018-12-27
PL2480675T3 (pl) 2017-03-31
PT2568049T (pt) 2016-07-11
MX2022002117A (es) 2022-03-17
CN104404050A (zh) 2015-03-11
AU2011271046A1 (en) 2013-01-31
IL259965B (en) 2019-02-28
IL291301B2 (en) 2023-07-01
KR101975884B1 (ko) 2019-05-10
LT3034608T (lt) 2019-05-27
NZ707198A (en) 2016-04-29
JP2016010417A (ja) 2016-01-21
EP3034608A1 (en) 2016-06-22
KR20220150430A (ko) 2022-11-10
KR20210013376A (ko) 2021-02-03
JP6341972B2 (ja) 2018-06-13
ES2576928T3 (es) 2016-07-12
CN104342455B (zh) 2017-05-31
SG10201504568YA (en) 2015-07-30
KR102193823B1 (ko) 2020-12-22
JP6073441B2 (ja) 2017-02-01
SMT201900241T1 (it) 2019-05-10
KR20200143511A (ko) 2020-12-23
EP2480676B1 (en) 2016-04-06
EP2905338B8 (en) 2018-01-24
KR102118565B1 (ko) 2020-06-03
HK1226766A1 (en) 2017-10-06
CY1118126T1 (el) 2017-06-28
JP2023133554A (ja) 2023-09-22
EP2905338A1 (en) 2015-08-12
HUE036597T2 (hu) 2018-07-30
JP2020128440A (ja) 2020-08-27
HRP20160794T1 (hr) 2016-08-12
US9150662B2 (en) 2015-10-06
US20150176002A1 (en) 2015-06-25
AU2011271043A8 (en) 2016-01-21
US20150351371A1 (en) 2015-12-10
CA2803864C (en) 2017-05-16
ES2646052T3 (es) 2017-12-11
EP2568049A1 (en) 2013-03-13
KR20180135996A (ko) 2018-12-21
US9226484B2 (en) 2016-01-05
JP6009441B2 (ja) 2016-10-19
KR101970944B1 (ko) 2019-04-23
SG186390A1 (en) 2013-01-30
RS54891B1 (sr) 2016-10-31
IL313063A (en) 2024-07-01
CN103068993B (zh) 2016-01-06
SMT201600212B (it) 2016-08-31
IL247386A (en) 2017-07-31
US20150173332A1 (en) 2015-06-25
KR20200064166A (ko) 2020-06-05
RU2601297C2 (ru) 2016-10-27
PT2480675T (pt) 2016-07-11
US20150246977A1 (en) 2015-09-03
US20130326647A1 (en) 2013-12-05
AU2011271043A1 (en) 2013-01-31
DK2568049T3 (en) 2016-08-01

Similar Documents

Publication Publication Date Title
ME02440B (me) Miševi koji ispoljavaju laki lanac sa ljudskim lambda promenljivim regionom i mišjim konstantnim regionom
Prashanth et al. The role of defensive ecological interactions in the evolution of conotoxins
Luna-Ramirez et al. Whole transcriptome of the venom gland from Urodacus yaschenkoi scorpion
ES2553331T3 (es) Nuevos genes marcadores seleccionables
Fraser et al. The odontode explosion: the origin of tooth‐like structures in vertebrates
HRP20191895T4 (hr) Adam6 miševi
CO6592013A2 (es) Combinacíones que incluyen proteínas cry3aa y cry6aa para prevenir el desarrollo de reistencia en gusanos de la raiz de maiz (diabrotica spp.)
BR112015002280A2 (pt) produção de gado resistente a vfa por substituição de alelo
MX379274B (es) Animales no humanos humanizados con loci de cadena pesada de inmunoglobulina restringidos.
ATE401363T1 (de) Zusammensetzungen und verfahren zur herstellung von zusammensetzungen mit brennstoffbeständigkeit
BR112017007431A2 (pt) compósitos termoplásticos de fibra longa híbridos
JP2017514496A5 (me)
EA201690759A1 (ru) Генетические маркеры, позволяющие прогнозировать ответ на ацетат глатирамера
ES2575906T3 (es) Composiciones y métodos de producir metionina
BR112013009157A2 (pt) polipeptídeos com atividade de permease
BR112013004124A2 (pt) peptídeo ou complexo de peptídeos ligando a alfa2 integrina e métodos e utilizações envolvendo os mesmos
MX2015004060A (es) 3-epimerasa.
BRPI0910461A2 (pt) fsh recombinante incluindo sialilação alfa 2,3 e alfa 2,6
Haapa-Paananen et al. Phylogenetic analysis of Maverick/Polinton giant transposons across organisms
Jones et al. The alveolate translation initiation factor 4E family reveals a custom toolkit for translational control in core dinoflagellates
MX2021000788A (es) Composiciones de anticuerpos del receptor de fc (fcrn).
Klink et al. Spread of endemic SARS-CoV-2 lineages in Russia before April 2021
PE20120400A1 (es) Contrucciones de casb7439
MX2023006846A (es) Microorganismo que expresa una proteina derivada de shewanella oneidensis y metodo para producir l-aminoacido usando el mismo.
ATE447414T1 (de) Verwendung aktivierter polymere zur trennung von protein- und polypeptid-multimeren